PIONEER Big Data in Prostate Cancer Platform Opens up to Asian Data Sets
PIONEER and the Chinese University of Hong Kong Started a Big Data Collaboration to Fight Prostate Cancer Worldwide
The European funded prostate cancer project PIONEER – Big Data in Prostate Cancer and the Faculty of Medicine of The Chinese University of Hong Kong have signed a data sharing agreement to ensure more data diversity and a better representation of men worldwide. The cooperation already started in October 2022 and is now taking shape through the harmonisation of the data sets followed by their integration into the PIONEER Big Data Platform. The provision of the 2000 data from Asia shall mark the starting point of further European-Asian cooperation in this field.
PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope) is an European Network of Excellence for Big Data in Prostate Cancer, consisting of 36 private and public stakeholders in prostate cancer research and clinical care from across 9 countries. Through unlocking the potential of Big Data and the generation of Real-World Evidence, PIONEER aims to change the prostate cancer landscape to improve the health and social care received by all prostate cancer patients and their families.
So far 27 data sets are available in the PIONEER Big Data Platform and four data sets are currently being mapped to the OMOP-CDM. The Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) is an open community data standard, designed to standardize the structure and content of observational data and to enable efficient analyses that can produce reliable evidence.

Overview figure of the PIONEER data sources
To ensure the highest possible diversity of data, the international project team is always grateful for the provision of additional data by external providers, as has now been done by the Faculty of Medicine, The Chinese University of Hong Kong (CUHK).
Dr. Susan Evans Axelsson, PIONEER Private Project Leader and Medical Advisor at Bayer AB:
“There is a measurable impact of having diversity in data, which allows for the assessment of differences across geographies and populations. This is especially true for men with prostate cancer, since it is such a heterogeneous disease. CUHK, is the first, but hopefully not the last partner from Asia to join PIONEER. Their data contribution and active involvement in the PIONEER project is helping to ensure the robustness of the platform by helping to provide a true representation of men worldwide. By building a data platform that contains data from men around the world, questions can be answered to identify essential differences in populations, for instance, differences in drug response, drug related adverse events, treatment availability, therapeutic options and clinical care across geographies. We are excited about this collaboration, and we welcome Dr. Jeremy Teoh and his team at CUHK with open arms.”
The Chinese University of Hong Kong contributes to the central PIONEER Big Data platform by providing observational data from their Prostate Cancer Registry. The registry includes data from 2,000 patients diagnosed with prostate cancer of all stages collected since 2016. The two partners report on the collaboration so far and invite further Asian data contributors to join the team and support to close critical evidence gaps in prostate cancer by analysing large sets of real-world data.
Jeremy Teoh, Associate Professor of the Faculty of Medicine of CUHK in Hong Kong:
“The PIONEER project represents the largest database in prostate cancer. With big data analysis, PIONEER can provide valuable information regarding the management of prostate cancer. Ethnic differences exist and it is important to incorporate data from Asian patients to this dataset. PIONEER values collaboration with Asian partners and I strongly encourage other Asian centres to join this important global initiative. With PIONEER, we will understand a lot more about the differences in the biology of prostate cancer between Caucasian and Asian patients.”
With more than 1.4 million new prostate cancer cases and almost 400 thousand deaths per year, prostate cancer is the second most commonly diagnosed cancer and the fifth leading cause of cancer death among men worldwide. There is thus an urgent need to exploit the potential of big data for a better diagnose and treatment of prostate cancer. By applying advanced data analytics, and developing a data-driven platform of unparalleled scale, quality and diversity, PIONEER will empower meaningful improvement in clinical practice, prostate cancer disease-related outcomes, and health-economic outcomes across the healthcare landscapes.
PIONEER is part of the Innovative Medicine Initiative’s (IMI’s) “Big Data for Better Outcomes” (BD4BO) umbrella programme. The BD4BO mission is to improve health outcomes and healthcare systems in Europe by maximising the potential of Big Data.
INTERESTED IN SHARING DATA?
If you have data sets of prostate cancer patients already mapped to OMOP-CDM and are interested to collaborate, please contact pioneer.info@uroweb.org!
WHY SHARING DATA?
Only if we work together and share data, we can build up a big data platform that can provide the information we need to combat prostate cancer.
Further information
www.prostate-pioneer.eu
Twitter: @ProstatePioneer
LinkedIn: PIONEER – Big Data in Prostate Cancer

PIONEER project contacts
PIONEER Contact:
Project Coordinator: Prof. James N’Dow, EAU
Private Project Leader: Dr. Susan Evans Axelsson, Bayer AB
Project Communications: Dr. Monika Maaß, Monika.Maass@arttic-innovation.de
Press Relations: Verena von Scharfenberg, press@arttic-innovation.de
CUHK Contact:
Prof. Jeremy Teoh, Associate Professor of the Faculty of Medicine, CUHK, jeremyteoh@surgery.cuhk.edu.hk
Emmy Wai Sum Lee, Director of Media and Communications at the faculty, emmylee@cuhk.edu.hk
PIONEER is a European project funded through IMI2 JU, and is listed under grant agreement No. 777492. IMI2 receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views communicated within are those of PIONEER. Neither the IMI nor the European Union, EFPIA or any associated partners are responsible for any use that may be made of the information contained herein.
ARTTIC Innovation GmbH has been advising research and innovation projects for more than 33 years. As project management and communication partner, we make sure that our projects run successfully and that project results and events are disseminated in the best possible way. ARTTIC is a subsidiary of the PNO Group, one of the largest consultancies for publicly funded projects in research and development. For more information, please visit www.arttic-innovation.de.
R&D tax credits (Forschungszulage) or ZIM? A choice without agony
R&D tax credits (Forschungszulage) or ZIM? - A choice without agony -R&D tax credits vs. ZIM: The initial scenarioIn practice, small and medium-sized enterprises (SMEs) ask themselves which national funding programme they should pursue for their research and...
POWERBASE facilitates green transition of emergency response organisations
POWERBASE project improves working conditions and facilitates the green transition of emergency response organisations.Twelve emergency response and research organisations have joined forces to prepare future procurement of renewable energy technologies to set the...
Senior Innovation Consultant (m/f/d)
We offer you the unique opportunity to become part of a dynamic team in the attractive field of innovation and research. We are looking for specialists with a passion for innovation, scientific writing and project management. This position is for experienced...
Junior Funding Consultant (m/f/d)
We offer you the unique opportunity to become part of a successful & young team in the attractive growth market for tax-incentivised research funding (R&D tax credits). We are looking for Junior Funding Consultants with a passion for innovation, scientific...
Why the carousel of amendments to the R&D tax credit law continues to turn
The R&D tax credits in 2024The year 2024 has proven to be decisive for the German R&D tax credits. Following the most recent amendment as part of the Growth Opportunities Act in March, the Federal Government realized during the budget consultations for 2025...
Register Now: In Conversation with EBiSC2
Unlocking the Potential of Stem Cells: Discover the EBiSC Journey to SustainabilityJoin the conversation on the initiative that’s shaping the future of biomedical research! On May 15, 2024, from 14:15 to 15:00 CEST (Europe/Brussels time), the Innovative Health...
The R&D tax credit with a blind eye to earnings –
Why loss-making companies (wrongly) hesitate
Recapitulation The German R&D tax credit has become much more popular in recent years after a modest response following the introduction of the instrument. This can be seen not only in advertising and studies by various associations, but also in the bare figures...
First successful demonstration with 100% green H2
HYFLEXPOWER celebrates successful operation of a gas turbine with 100% green H2On October 12, 2023, at a public event hosted at the HYFLEXPOWER demonstrator site in Saillat-sur-Vienne, France, the HYFLEXPOWER consortium unveiled a ground-breaking achievement - the...
New Security Project AGILE Will Improve Disaster Risk Management
New international security project to improve disaster risk management for unexpected eventsThe international security project AGILE will kick start today. The project is to develop novel tools and methodologies for understanding, anticipating, and managing High...
How the government’s draft of the Growth Opportunities Act refines the research allowance
Government draft of the Growth Opportunities ActThe government draft of the submitted Growth Opportunities Act has once again undergone a significant redesign compared to the draft bill (§ 33 from p. 71). The revision regarding the Research Grants Act rewards small...